Raab resurfaces quickly: FDA rhetoric belies reality of calendar

Experience outweighs short-term negative perceptions, in the view of Shaman Pharmaceuticals Inc., which elevated G. Kirk Raab to chairman of the board.

Raab, who resigned as president and CEO at Genentech Inc. in July after GNE's board learned that he had solicited a $2 million personal bank loan guarantee from partner Roche and reviewed his overall leadership, has been a member of SHMN's board for two-and-a-half years. ...